Does COVID-19 cause an increased risk of hospitalization or death in patients with inflammatory rheumatic diseases treated with biological DMARDs or targeted synthetic DMARDs?
May Lwin(University Hospital Southampton NHS Foundation Trust), Christopher J Edwards(University Hospital Southampton NHS Foundation Trust), Christopher Holroyd(Southampton General Hospital), Brian Davidson(University Hospital Southampton NHS Foundation Trust), Dinny Wallis(University Hospital Southampton NHS Foundation Trust), Lyndsey Goulston(National Institute for Health and Care Research), Hans de Graaf(NIHR Southampton Biomedical Research Centre)
Cited by 1
Related Papers
EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2019 update
|Annals of the Rheumatic Diseases|2020|2.8k
EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2022 update
|Annals of the Rheumatic Diseases|2022|1.9k
2022 update
|Radboud Repository (Radboud University)|2010|1.6k
EULAR recommendations for the use of imaging of the joints in the clinical management of rheumatoid arthritis
|Annals of the Rheumatic Diseases|2013|668
Vitamin D supplementation in pregnancy: a systematic review
|Health Technology Assessment|2014|353